Sunita Koparkar

Safety Science Director
Genentech, Inc.

Presentation(s):

• OC 30.5 - Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

  Monday, July 11, 2022
  11:45 AM – 12:00 PM